Sertraline
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Sertraline: From Anxiety Disorders to Schizotypal Personality Disorder
One-Sentence Summary
Sertraline is a selective serotonin reuptake inhibitor (SSRI) originally used for anxiety-spectrum conditions such as obsessive-compulsive disorder, post-traumatic stress disorder and social phobia. The TxGNN model predicts it may be effective for schizotypal personality disorder, but support is very thin: 1 small clinical trial (8 participants) and 1 publication that does not address this condition. The Evidence Pack's top-ranked prediction is therefore a computational signal only, and other predicted indications (panic disorder with agoraphobia, major depressive disorder) have far stronger support. They are noted in the conclusion.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder, post-traumatic stress disorder, social phobia, phobic disorder, obsessive-compulsive disorder (from the knowledge graph; the Singapore licences list no indication text) |
| Predicted New Indication | Schizotypal personality disorder |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, sertraline is an SSRI that increases serotonin signalling by blocking its reuptake. Its efficacy in anxiety, obsessive-compulsive and trauma-related disorders is established.
Schizotypal personality disorder involves attenuated psychotic-like symptoms (unusual thoughts, suspiciousness) along with social anxiety and negative symptoms. Serotonergic modulation could plausibly affect some of these features, which is the likely basis for the model's prediction.
However, this link is speculative. The only trial is a tiny exploratory study of sertraline alone versus combined with risperidone in an attenuated-symptom population. The single cited publication concerns obsessive-compulsive disorder with anorexia nervosa and is not relevant to schizotypal disorder. The prediction should be regarded as a hypothesis, not a supported indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00169988 | NA | Completed | 8 | Sertraline alone vs. with risperidone for attenuated positive and negative symptoms in adolescents (2004–2007). Exploratory design; no efficacy conclusions possible |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37082034 | 2021 | Case report | Postepy psychiatrii neurologii | Comorbid OCD and anorexia nervosa in a 14-year-old girl; discusses diagnostic difficulty and is not relevant to schizotypal disorder |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07301P | ZOLOFT TABLET 50 mg | Tablet, film coated | Not specified |
| SIN13467P | Apo-Sertraline 50mg Tablet | Tablet, film coated | Not specified |
| SIN13315P | Apo-Sertraline 50mg Capsule | Capsule | Not specified |
| SIN14790P | INOSERT 50 TABLET 50mg | Tablet, film coated | Not specified |
| SIN14789P | INOSERT 100 Tablet 100mg | Tablet, film coated | Not specified |
Seven valid single-ingredient licences are registered in total. The two others are SERNADE film-coated tablet 50 mg (SIN16649P) and SETROF tablet 50 mg (SIN14221P).
Safety Considerations
- Disease contraindications flagged in the knowledge graph (not taken from label text): epilepsy, bipolar disorder, major affective disorder, liver disease, gallbladder disease, blood coagulation disease, neuroleptic malignant syndrome, inappropriate ADH syndrome (SIADH), nephrogenic syndrome of inappropriate antidiuresis, and serotonin syndrome.
- Drug interactions: 100 interactions were identified. Those rated Major include bupropion, lorcaserin, diethylpropion, dolasetron, eliglustat, palonosetron and phentermine. Moderate examples include aspirin, morphine, clarithromycin, famotidine, loperamide and several sulfonylureas or insulin.
Package insert warnings and contraindications could not be obtained for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Support for schizotypal personality disorder is limited to a high model score, one 8-participant exploratory trial and one irrelevant case report. This is below the threshold for efficacy conclusions. The same is true of the other personality-disorder predictions (schizoid, histrionic, paranoid, dependent, narcissistic), which have no trials or only indirect literature.
Other predicted indications in the data (for reference):
- Agoraphobia (panic disorder with or without agoraphobia): Evidence L1, Proceed with Guardrails. Supported by double-blind sertraline trials, comparator studies and network meta-analyses. It is largely an extension within the existing anxiety-spectrum use.
- Major depressive disorder and endogenous depression: Evidence L1, Proceed with Guardrails. These are well-established uses, not novel repurposing. The indication list in this record omits MDD, so labeling should be verified.
To proceed, the following is needed:
- Adequately powered, controlled trials of sertraline in schizotypal personality disorder
- Mechanism of action data to support the proposed link
- Package insert warnings and contraindications from the HSA
- Approved indication text for the Singapore licences
- Safety review for the adolescent and young-adult populations (suicidality monitoring) and for the large interaction burden, especially the Major-rated combinations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.